MIAMI, March 22, 2022–(BUSINESS WIRE)–ECP Pharma, an early-stage pharmaceutical agency, led by among the greatest minds from a cross part of healthcare and pharmaceutical expertise, is already properly on its method to creating novel medication for focused indications with no clinically confirmed remedy choices utilizing underutilized APIs (Energetic Pharmaceutical Substances).
ECP Pharma is a worldwide firm with operations in america, Canada, and Latin America that’s dedicated to analysis, growth & manufacturing of modern drug merchandise that improve human life. Based in March 2019 with its company headquarters in Miami, ECP Pharma is on monitor to start medical trials this yr in america and a secondary website in Latin America for its main drug candidate.
“It has been a dream of mine for 20 years to search out secure pharmaceutical therapies to deal with the implications of head trauma/mind accidents,” says Dr. Michael Hoffer, ECP Pharma’s Chief Medical Officer and a Professor of Otolaryngology and Neurological Surgical procedure on the College of Miami. “After treating these kind of accidents frequently throughout my profession within the U.S. Navy and in educational observe, I wished to be concerned with a corporation that might make these kind of options obtainable and remodel the best way these accidents are handled. ECP Pharma has all the proper components behind it, together with the group and other people to maneuver it by.”
In accordance with Dr. Hoffer, ECP Pharma’s focus and areas of analysis goal the sector of neuroscience and neurology to establish goal indications to develop a strong drug product growth pipeline. It’s drug discovery course of and enterprise growth analytics are backed by world-class specialists within the fields of drug analysis, regulatory compliance, and enterprise administration. The corporate’s distinctive collaboration with the College of Miami’s Miller College of Drugs by analysis agreements offers one other strategic edge for ECP Pharma.
The ECP Pharma medical trials group is at present in discussions with regulatory companies in North and South America to have the ability to bear a number of complete, inclusive trials along with Part 1 and a couple of medical trials set to start in Miami, Florida. A number of new FDA authorized diagnostic applied sciences that the corporate is using will permit it to quantify the advance in every affected person’s situation after the remedy course has been administered.
ECP Pharma’s distinctive product pipeline makes use of a mixture of cannabinoids, psychedelics and different compounds to therapeutically deal with illness indications from which hundreds of thousands of sufferers undergo worldwide. For extra details about ECP Pharma and its work throughout a number of medical and practical areas go to www.ecppharma.com.
About ECP Pharma Inc.
ECP Pharma Inc. is a clinical-stage pharmaceutical firm centered on treating neurological and CNS ailments. The Firm’s product pipeline contains medication derived from cannabinoids, psychedelic and different compounds to supply potential therapeutic profit to a number of central nervous system ailments resembling spasticity for A number of Sclerosis, delicate cognitive impairment for early on set of Alzheimer’s Illness and delicate Traumatic Mind Damage (mTBI). Extra info could also be discovered on the corporate’s web site www.ecppharma.com
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220322005572/en/
John Stellar / Everybody’s PR (818) 853-7100